

# Kyowa Kirin Co., Ltd.

## Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 First Quarter

(January 1, 2026 - March 31, 2026)

- These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on May 7, 2026 for the first three months of Fiscal 2026, from January 1, 2026 to March 31, 2026.
- This document is an English translation of the Japanese-language original.
- The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
- For the "FY 2026 forecasts" within these materials, revisions have been made to the forecasts announced on February 9, 2026
- Figures presented in these materials have been rounded to the nearest tenth
- Figures inside parenthesis presented in these materials indicate negative values.
- Change amount in these materials presents change amount compared to the same period of the previous fiscal year.

Index	Page
I. Consolidated Financial Results	
1. Trends in consolidated profit	1
2. Revenue by regional control function	2
3. Capital expenditures and intangible assets investment, depreciation and amortization	2
4. Number of employees by regional control function	2
II. Consolidated Statement of Cash Flows	2
III. Status of Main Products	
1. Revenue by Products	3
2. Revenue by Location	4
3. Collaboration Products	5
IV. R&D Pipeline	6

The average exchange rates for each period were as follows:

*Unit: Yen*

	FY 2025 results				FY 2026	FY2026
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	results	forecasts
	Jan - Mar	Jan - Dec	Jan - Mar	Jan - Dec	Jan - Mar	Jan - Dec
USD	154	150	149	150	155	150
GBP	193	193	195	197	210	205
EUR	161	162	165	168	183	180

<p>Contact            Kyowa Kirin Co., Ltd.            Finance Department            Tel +81 3 5205 7206</p>
--

## I. Consolidated Financial Results

### 1. Trends in consolidated profit

Unit: Billions of yen

	FY 2025 results				FY 2026 results			FY 2026 forecasts		FY 2028 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	Rate of change	Jan - Dec	Progress	
Revenue	104.7	230.7	349.5	496.8	118.5	13.7	13%	520.0	23%	
Cost of sales	(24.6)	(61.9)	(90.1)	(127.9)	(30.2)	(5.6)	23%	(132.0)	23%	
Gross profit	80.1	168.8	259.4	368.9	88.2	8.1	10%	388.0	23%	
<i>Gross profit to revenue ratio</i>	76.5%	73.2%	74.2%	74.2%	74.5%	-	-	74.6%	-	
Selling, general and administrative expenses <sup>2</sup>	(40.4)	(79.5)	(116.5)	(157.9)	(41.1)	(0.7)	2%	(163.0)	25%	
Research and development expenses	(28.6)	(52.5)	(76.8)	(101.2)	(27.2)	1.4	(5)%	(95.0)	29%	
<i>R&amp;D expense ratio</i>	27.3%	22.8%	22.0%	20.4%	22.9%	-	-	18.3%	-	
Core operating profit <sup>1</sup>	11.2	36.8	66.1	109.8	20.0	8.8	78%	130.0	15%	
<i>Core operating profit ratio</i>	10.7%	16.0%	18.9%	22.1%	16.9%	-	-	25.0%	-	Early 20% range
Amortization (intangible assets) <sup>2</sup>	(1.7)	(3.4)	(5.1)	(7.6)	(2.8)	(1.1)	64%	(11.0)	25%	
Share of profit (loss) of investments accounted for using equity method	(0.9)	1.5	1.0	0.8	1.0	1.9	-	-	-	
Other income	0.4	0.6	0.7	1.1	0.4	(0.0)	(3)%	-	-	
Other expenses	(1.6)	(12.9)	(14.7)	(18.0)	(8.1)	(6.5)	410%	-	-	
Finance income (costs)	0.4	(0.7)	(0.1)	1.1	3.4	3.0	691%	-	-	
Profit before tax	7.9	22.0	47.9	87.2	13.9	6.1	77%	95.0	15%	
Income tax expense	(1.7)	(5.7)	(15.3)	(20.2)	(1.9)	(0.2)	12%	(20.0)	9%	
<i>Ratio of income tax burden</i>	21.5%	25.7%	32.0%	23.1%	13.6%	-	-	-	-	
Profit	6.2	16.3	32.6	67.0	12.0	5.9	95%	75.0	16%	
<i>Profit to revenue ratio</i>	5.9%	7.1%	9.3%	13.5%	10.2%	-	-	14.4%	-	

ROE(%)	7.7	-	8.2	-
ROE(%) ※ Three-year average	8.3	-	7.7	-
DOE(%) <sup>3</sup>	3.8	-	4.1	-

Mid 7% range  
Progressive payout of 4% or more

<Accumulative>

	FY 2025 results				FY 2026 results			FY 2026 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	Rate of change	Jan - Dec	Progress
Core operating profit <sup>1</sup>	11.2	36.8	66.1	109.8	20.0	8.8	78%	130.0	15%
Income tax expense	(2.4)	(9.5)	(21.1)	(25.4)	(2.7)	(0.3)	12%	(27.0)	10%
<i>Ratio of income tax burden</i>	21.5%	25.7%	32.0%	23.1%	13.6%	-	-	-	-
Core Profit <sup>1</sup>	8.8	27.4	44.9	84.4	17.3	8.5	96%	103.0	17%
Core EPS (¥/share) <sup>4</sup>	16.83	52.25	85.85	161.28	33.04	16.21	-	196.76	-

<sup>1</sup> We have adopted core indicators as performance metrics that offer better comparability with global pharma, reflecting group's sustainable profitability.

The core operating profit is calculated by deducting selling, general and administrative expenses (excl. amortization of intangible assets) and research and development expenses from gross profit, and further excluding non-recurring items determined by the Company.

The core profit for the period is calculated by deducting income tax expense attributable to the relevant core operating profit from the core operating profit.

<sup>2</sup> Selling, general and administrative expenses do not include amortization of intangible assets (amortization of marketing rights).

<sup>3</sup> DOE is calculated by dividing the dividend amount by the beginning-of-period capital.

<sup>4</sup> The core EPS is calculated by dividing the core profit for the period by the weighted average number of shares outstanding during the period.

<sup>5</sup> For the actual results in 2025 and 2026 and the forecast for 2026, the Company did not exclude any items as non-recurring gains or losses, as determined by the Company.

<Quarterly>

Unit: Billions of yen

	FY 2025 results				FY 2026 results		
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change amount	Rate of change
Revenue	104.7	125.9	118.8	147.4	118.5	13.7	13%
Cost of sales	(24.6)	(37.3)	(28.2)	(37.9)	(30.2)	(5.6)	23%
Gross profit	80.1	88.7	90.6	109.5	88.2	8.1	10%
<i>Gross profit to revenue ratio</i>	76.5%	70.4%	76.3%	74.3%	74.5%	-	-
Selling, general and administrative expenses	(40.4)	(39.1)	(37.0)	(41.4)	(41.1)	(0.7)	2%
Research and development expenses	(28.6)	(23.9)	(24.3)	(24.3)	(27.2)	1.4	(5)%
<i>R&amp;D expense ratio</i>	27.3%	19.0%	20.5%	16.5%	22.9%	-	-
Core operating profit	11.2	25.6	29.2	43.8	20.0	8.8	78%
<i>Core operating profit ratio</i>	10.7%	20.3%	24.6%	29.7%	16.9%	-	-
Amortization (intangible assets)	(1.7)	(1.7)	(1.7)	(2.5)	(2.8)	(1.1)	64%
Share of profit (loss) of investments accounted for using equity method	(0.9)	2.5	(0.6)	(0.2)	1.0	1.9	-
Other income	0.4	0.2	0.2	0.3	0.4	(0.0)	(3)%
Other expenses	(1.6)	(11.3)	(1.9)	(3.3)	(8.1)	(6.5)	410%
Finance income (costs)	0.4	(1.2)	0.7	1.1	3.4	3.0	691%
Profit before tax	7.9	14.1	25.9	39.3	13.9	6.1	77%
Income tax expense	(1.7)	(4.0)	(9.7)	(4.9)	(1.9)	(0.2)	12%
Profit	6.2	10.2	16.3	34.4	12.0	5.9	95%
<i>Profit to revenue ratio</i>	5.9%	8.1%	13.7%	23.4%	10.2%	-	-

<Quarterly>

	FY 2025 results				FY 2026 results		
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change amount	Rate of change
Core operating profit	11.2	25.6	29.2	43.8	20.0	8.8	78%
Income tax expense	(2.4)	(7.1)	(11.6)	(4.3)	(2.7)	(0.3)	12%
Core Profit	8.8	18.5	17.6	39.5	17.3	8.5	96%

<sup>1</sup>The underlined portion indicates that the amount has been changed from the amount presented in "Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2025" (announced on February 9, 2026)

## 2. Revenue by regional control function

<Accumulative>

Unit: Billions of yen

	FY 2025 results				FY 2026 results		FY 2026 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	Jan - Dec	Progress
Japan	27.2	58.4	89.7	122.5	26.2	(0.9)	111.5	24%
North America	35.5	88.4	129.9	192.5	36.2	0.7	211.0	17%
EMEA	19.7	37.0	62.4	83.7	23.1	3.4	78.5	29%
Others	22.3	46.9	67.5	98.1	32.9	10.6	119.0	28%
<b>Total consolidated revenue</b>	<b>104.7</b>	<b>230.7</b>	<b>349.5</b>	<b>496.8</b>	<b>118.5</b>	<b>13.7</b>	<b>520.0</b>	<b>23%</b>
Japan (location of customer)	28.3	63.1	96.0	128.8	27.7	(0.6)	120.0	23%
Overseas (location of customer)	76.4	167.6	253.4	368.0	90.8	14.4	400.0	23%
Overseas ratio	73%	73%	73%	74%	77%	-	77%	-

\* Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin (OKK) matrix global management structure, which combines a regional organization, a functional organization, and a product organization (product franchises).

\* EMEA consists of Europe, the Middle East, Africa, etc.

\* Others consists of revenue from technology out-licensing, revenue from APAC, hematopoietic stem cell gene therapy (revenue from Orchard Therapeutics), original equipment manufacturing, etc.

<Quarterly>

Unit: Billions of yen

	FY 2025 results				FY 2026 results	
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change amount
Japan	27.2	31.2	31.3	32.8	26.2	(0.9)
North America	35.5	52.8	41.5	62.6	36.2	0.7
EMEA	19.7	17.3	25.3	21.3	23.1	3.4
Others	22.3	24.5	20.6	30.6	32.9	10.6
<b>Total consolidated revenue</b>	<b>104.7</b>	<b>125.9</b>	<b>118.8</b>	<b>147.4</b>	<b>118.5</b>	<b>13.7</b>

## 3. Capital expenditures and intangible assets investment, depreciation and amortization

Unit: Billions of yen

	FY 2025 results				FY 2026 results	FY 2026 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Dec
Capital expenditures (property, plant and equipment) <sup>*1</sup>	8.2	14.9	22.9	35.8	8.6	33.9
Intangible assets investment	1.3	9.9	21.3	48.1	2.2	18.3
<b>Total</b>	<b>9.4</b>	<b>24.9</b>	<b>44.2</b>	<b>83.9</b>	<b>10.8</b>	<b>52.2</b>
Depreciation (property, plant and equipment)	3.8	7.6	11.7	15.8	4.2	16.8
Amortization (intangible assets)	2.3	4.7	7.1	10.4	3.4	15.0
Of which, sales right <sup>*2</sup>	1.7	3.4	5.1	7.6	2.8	11.0
<b>Total</b>	<b>6.1</b>	<b>12.3</b>	<b>18.8</b>	<b>26.1</b>	<b>7.6</b>	<b>31.7</b>

\*1 Acquisitions of right-of-use assets are not included.

\*2 Amortization of sales right is presented as amortization of intangible assets in the consolidated statement of profit or loss.

## 4. Number of employees by regional control function

	FY 2025 results				FY 2026 results	
	As of Mar 31	As of Jun 30	As of Sep 30	As of Dec 31	As of Mar 31	Change amount
Japan	3,898	3,890	3,882	3,508	3,483	(415)
North America	709	678	699	706	740	31
EMEA	538	540	544	551	540	2
Others	375	381	387	397	402	27
<b>Total</b>	<b>5,520</b>	<b>5,489</b>	<b>5,512</b>	<b>5,161</b>	<b>5,165</b>	<b>(355)</b>

\* Others consists of number of employees of APAC subsidiaries, Orchard Therapeutics, etc.

## II. Consolidated Statement of Cash Flows

Unit: Billions of yen

	FY 2025 results				FY 2026 results	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount
<b>Cash flows from operating activities</b>	<b>7.4</b>	<b>39.8</b>	<b>69.6</b>	<b>96.6</b>	<b>56.3</b>	<b>48.9</b>
<b>Cash flows from investing activities</b>	<b>(21.5)</b>	<b>(34.7)</b>	<b>(41.6)</b>	<b>(89.2)</b>	<b>(8.6)</b>	<b>12.9</b>
<b>Cash flows from financing activities</b>	<b>(16.5)</b>	<b>(17.2)</b>	<b>(33.6)</b>	<b>(36.9)</b>	<b>(17.9)</b>	<b>(1.4)</b>
Effect of exchange rate changes on cash and cash equivalents	0.3	2.0	1.2	3.5	0.9	0.6
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(30.3)</b>	<b>(10.1)</b>	<b>(4.5)</b>	<b>(25.9)</b>	<b>30.8</b>	<b>61.1</b>
Cash and cash equivalents at beginning of period	244.7	244.7	244.7	244.7	218.8	(25.9)
<b>Cash and cash equivalents at end of period</b>	<b>214.4</b>	<b>234.6</b>	<b>240.2</b>	<b>218.8</b>	<b>249.5</b>	<b>35.2</b>

### III. Status of Main Products

#### 1. Revenue by Products

<Accumulative>

Unit: Billions of yen

	FY 2025 results				FY 2026 results		FY 2026 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	Jan - Dec	Progress
Products <sup>*1</sup>	91.8	205.2	310.1	438.4	93.6	1.9	445.1	21%
Crysvita	42.4	99.8	146.7	216.4	45.7	3.2	235.4	19%
Poteligeo	9.8	21.6	33.7	45.7	12.1	2.3	54.6	22%
Libmeldy/Lenmeldy	2.1	4.4	4.4	6.4	1.5	(0.6)	10.0	15%
Nourianz	2.0	4.6	6.9	9.5	1.9	(0.1)	7.4	25%
PHOZEVEL	1.5	3.7	5.9	8.2	1.9	0.4	11.6	17%
Duvroq	3.0	6.9	10.9	15.5	3.6	0.6	16.2	22%
Nesp	0.5	0.9	1.1	1.4	0.2	(0.3)	0.8	25%
Darbepoetin Alfa Injection Syringe [KKF]	2.3	4.9	7.6	10.4	2.2	(0.1)	9.2	24%
G-Lasta	4.3	9.1	13.7	18.2	3.5	(0.8)	16.2	22%
Romiplate	3.4	7.3	11.5	15.9	3.7	0.3	11.4	33%
Orkedia	2.4	5.4	8.2	11.3	2.4	0.0	11.6	21%
Rituximab BS [KHK]	1.5	3.2	5.0	6.9	1.5	(0.0)	5.7	27%
Nourias	1.4	3.1	4.6	6.3	1.3	(0.1)	5.1	25%
HARUROPI	1.0	2.1	3.3	4.5	1.0	(0.0)	4.0	24%
Technology out-licensing <sup>*2</sup>	13.0	25.5	39.4	58.4	24.8	11.9	74.9	33%
Benralizumab royalty <sup>*3</sup>	7.4	15.7	25.4	38.1	8.6	1.2		
<b>Total</b>	<b>104.7</b>	<b>230.7</b>	<b>349.5</b>	<b>496.8</b>	<b>118.5</b>	<b>13.7</b>	<b>520.0</b>	<b>23%</b>

<Quarterly>

Unit: Billions of yen

	FY 2025 results				FY 2026 results	
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change amount
Products <sup>*1</sup>	91.8	113.4	104.9	128.3	93.6	1.9
Crysvita	42.4	57.3	46.9	69.7	45.7	3.2
Poteligeo	9.8	11.8	12.1	12.0	12.1	2.3
Libmeldy/Lenmeldy	2.1	2.3	(0.0)	2.0	1.5	(0.6)
Nourianz	2.0	2.6	2.3	2.6	1.9	(0.1)
PHOZEVEL	1.5	2.1	2.2	2.3	1.9	0.4
Duvroq	3.0	3.8	4.1	4.6	3.6	0.6
Nesp	0.5	0.4	0.3	0.3	0.2	(0.3)
Darbepoetin Alfa Injection Syringe [KKF]	2.3	2.6	2.7	2.8	2.2	(0.1)
G-Lasta	4.3	4.8	4.6	4.5	3.5	(0.8)
Romiplate	3.4	3.9	4.2	4.4	3.7	0.3
Orkedia	2.4	2.9	2.9	3.1	2.4	0.0
Rituximab BS [KHK]	1.5	1.7	1.8	1.8	1.5	(0.0)
Nourias	1.4	1.7	1.6	1.7	1.3	(0.1)
HARUROPI	1.0	1.2	1.1	1.3	1.0	(0.0)
Technology out-licensing <sup>*2</sup>	13.0	12.5	13.9	19.1	24.8	11.9
Benralizumab royalty <sup>*3</sup>	7.4	8.3	9.7	12.7	8.6	1.2
<b>Total</b>	<b>104.7</b>	<b>125.9</b>	<b>118.8</b>	<b>147.4</b>	<b>118.5</b>	<b>13.7</b>

<sup>\*1</sup> For revenue for Japan, the figures shown are those before the deduction of discounts and other items, and for revenue for overseas, the figures shown are those after the deduction of discounts and other items and include the impact of exchange rates.

<sup>\*2</sup> Revenue listed as "Technology out-licensing" represents the upfront income, milestone revenue and running royalty income that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

<sup>\*3</sup> Benralizumab royalty only refers to the royalty on sales of Fasenna by AstraZeneca (including the Company's own estimates).

### III. Status of Main Products

#### 2. Revenue by location

<Accumulative>

Unit: Billions of yen

Product name	FY 2025 results				FY 2026 results		FY 2026 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	Jan - Dec	Progress
Crysvita	42.4	99.8	146.7	216.4	45.7	3.2	235.4	19%
Japan	2.8	6.1	9.7	13.6	3.4	0.7	14.7	23%
North America	24.1	64.0	92.0	141.8	23.5	(0.6)	220.7	19%
[Millions of USD]	157	430	620	946	151	(5)		
EMEA	14.8	28.0	42.4	57.5	17.9	3.1		
[Millions of GBP]	77	145	219	293	85	8		
Others	0.8	1.7	2.6	3.5	0.9	0.1		
Poteligeo	9.8	21.6	33.7	45.7	12.1	2.3	54.6	22%
Japan	0.3	0.7	1.2	1.6	0.4	0.1	1.4	25%
North America	6.9	16.0	25.1	33.9	8.9	2.0	40.9	22%
[Millions of USD]	45	107	169	227	57	13	273	21%
EMEA	2.6	4.9	7.3	10.0	2.8	0.2	12.0	23%
[Millions of GBP]	13	25	38	51	13	0	59	23%
Others	0.0	0.1	0.1	0.2	0.0	(0.0)	0.2	9%
Libmeldy/Lenmeldy	2.1	4.4	4.4	6.4	1.5	(0.6)	10.0	15%
US	1.1	1.6	1.6	2.9	1.1	0.0	4.5	
EMEA	1.0	2.8	2.8	3.5	0.4	(0.6)	5.5	

<Quarterly>

Unit: Billions of yen

Product name	FY 2025 results				FY 2026 results	
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change amount
Crysvita	42.4	57.3	46.9	69.7	45.7	3.2
Japan	2.8	3.3	3.6	3.9	3.4	0.7
North America	24.1	39.9	28.0	49.8	23.5	(0.6)
[Millions of USD]	157	273	191	325	151	(5)
EMEA	14.8	13.2	14.4	15.1	17.9	3.1
[Millions of GBP]	77	68	74	74	85	8
Others	0.8	1.0	0.9	0.9	0.9	0.1
Poteligeo	9.8	11.8	12.1	12.0	12.1	2.3
Japan	0.3	0.4	0.5	0.5	0.4	0.1
North America	6.9	9.1	9.1	8.8	8.9	2.0
[Millions of USD]	45	62	62	58	57	13
EMEA	2.6	2.3	2.5	2.7	2.8	0.2
[Millions of GBP]	13	12	13	13	13	0
Others	0.0	0.0	0.0	0.1	0.0	(0.0)
Libmeldy/Lenmeldy	2.1	2.3	(0.0)	2.0	1.5	(0.6)
US	1.1	0.5	(0.0)	1.3	1.1	0.0
EMEA	1.0	1.8	(0.0)	0.7	0.4	(0.6)

\* The revenue, generated in various currencies inside each corporate region, is converted and aggregated in USD for North America and in GBP for EMEA.

### III. Status of Main Products

#### 3. Collaboration Product

<Accumulative>

Unit: Billions of yen

Product name	FY2025 results				FY2026 results	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount
<b>KOMZIFTI</b>						
Revenue <sup>*1</sup>	-	-	-	0.3		
[Millions of USD]	-	-	-	2		
Profit/Loss	(1.3)	(3.1)	(5.5)	(8.2)	(1.5)	(0.2)
[Millions of USD]	(8)	(20)	(37)	(55)	(9)	(1)
<b>Our group (50% share)<sup>*2</sup></b>						
Revenue	-	-	-	-	-	-
Selling, general and administrative expenses	(0.6)	(1.5)	(2.8)	(4.1)	(0.7)	(0.1)
Core operating profit	(0.6)	(1.5)	(2.8)	(4.1)	(0.7)	(0.1)
Amortization (intangible assets)	-	-	-	(0.7)	(1.1)	(1.1)
Profit before tax	(0.6)	(1.5)	(2.8)	(4.8)	(1.8)	(1.2)

<Quarterly>

Unit: Billions of yen

Product name	FY2025 results				FY2026 results	
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change amount
<b>KOMZIFTI</b>						
Revenue <sup>*1</sup>	-	-	-	0.3		
[Millions of USD]	-	-	-	2		
Profit/Loss	(1.3)	(1.8)	(2.5)	(2.7)	(1.5)	(0.2)
[Millions of USD]	(8)	(12)	(17)	(18)	(9)	(1)
<b>Our group (50% share)<sup>*2</sup></b>						
Revenue	-	-	-	-	-	-
Selling, general and administrative expenses	(0.6)	(0.9)	(1.2)	(1.3)	(0.7)	(0.1)
Core operating profit	(0.6)	(0.9)	(1.2)	(1.3)	(0.7)	(0.1)
Amortization (intangible assets)	-	-	-	(0.7)	(1.1)	(1.1)
Profit before tax	(0.6)	(0.9)	(1.2)	(2.1)	(1.8)	(1.2)

\*1 Revenue is expected to be disclosed following Kura Oncology's earnings call.

\*2 Under the strategic collaboration agreement with Kura Oncology, profits in the United States are been shared on a 50:50 basis. The Group records the net profit or loss after profit sharing as revenue when it is positive and as selling, general and administrative expenses when it is negative. Furthermore, the calculation of profit share may utilize the estimates.

## R&D pipeline

small molecule  
 antibody  
 HSC-GT

As of Mar 31, 2026

Code Name Generic Name Formulation		Mechanism of Action	Indication	Stage			[In-House or Licensed] Remarks
				PhI	PhII	PhIII	
	KK8123 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia				[In-House] Clinical study is being conducted in NA and EU as a global product
	KK8398 infigratinib Oral	FGFR3 Inhibitor	Achondroplasia				[QED Therapeutics] Clinical study is being conducted in JP
			Hypochondroplasia				Preparation underway for Ph III clinical trial in JP
	ziftomenib ※ Oral	Menin Inhibitor	Acute Lymphoblastic Leukemia (ALL) (Monotherapy)				[Kura Oncology] Clinical study is being conducted in NA and EU as a global product KMT2A-rearranged ALL KOMET-001
			Acute Myeloid Leukemia (AML) (Monotherapy)				Clinical study is being conducted in NA and EU as a global product Non-NPM1-mutant AML/Non-KMT2A-rearranged AML KOMET-001
							Adult Relapsed or Refractory AML with a NPM1 Mutation Preparation underway for Ph II clinical trial in JP
			Acute Myeloid Leukemia (AML) (Combination)				Clinical study is being conducted in NA as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin KOMET-007
							Clinical study is being conducted in NA as a global product FLT3/NPM1 co-mutated AML Combinations with cytarabine + daunorubicin, and quizartinib KOMET-007
							Clinical study is being conducted in NA and EU as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with gilteritinib, FLAG-IDA, LDAC KOMET-008
							Clinical study is being conducted as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin KOMET-017
	KK2845	Anti-TIM-3 ADC	Acute Myeloid Leukemia (AML)				[In-House] Antibody-Drug Conjugate Clinical study is being conducted in JP as a global product
	OTL-203	Hematopoietic Stem Cell (HSC) Gene Therapy	MPS-IH (Hurler Syndrome)				[In-House] Rare Pediatric Disease (RPD) and Fast Track designations (FDA) Priority Medicines (PRIME) designation (EMA) Area of clinical study: NA and EU
	OTL-201	Hematopoietic Stem Cell (HSC) Gene Therapy	MPS-III A (Sanfilippo Syndrome type A)				[In-House] Rare Pediatric Disease (RPD) designation (FDA) Preparation underway for registrational study (equivalent to Ph III study)
	KHK4951 tivozanib Ophthalmic	VEGF Receptor Tyrosine Kinase Inhibitor	Diabetic Macular Edema				[In-House] Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product
			Neovascular Age-Related Macular Degeneration				Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product
	KK2260 Injection	EGFR-TFR1 Bispecific Antibody	Advanced or Metastatic Solid Tumors				[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP, and a clinical study is prepared under way for Ph I in NA as a global product

## R&D pipeline

Code Name Generic Name Formulation		Mechanism of Action	Indication	Stage			[In-House or Licensed] Remarks
				PhI	PhII	PhIII	
	KK2269 Injection	EpCAM-CD40Bispecific Antibody	Advanced or Metastatic Solid Tumors	▶			[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP and NA as a global product
	KK4277 Injection	Anti-PTPRS Humanized Antibody	Systemic Lupus Erythematosus/Cutaneous Lupus Erythematosus	▶			[SBI Biotech] POTELLIGENT Clinical study is being conducted in JP and Asia
	KK3910 Injection		Essential Hypertension	▶			[In-House] Clinical study is being conducted in JP as a global product
	OTL-200 atidarsagene autotemcel	Hematopoietic Stem Cell (HSC) Gene Therapy	Early-onset Metachromatic Leukodystrophy (MLD)				[In-House] Orphan Regenerative Medicine Product Designation in JP A Ph.3 clinical study in JP is under preparation Product Name in US: Lenmeldy Product Name in Europe: Libmeldy
	KK2223		Cutaneous T cell lymphoma Peripheral T cell lymphoma				[In-House] Clinical study is prepared under way for Ph I

※ For detailed information on ziftomenib(Product Name in US: KOMZIFTI)'s development status, please refer to Kura Oncology's website. <https://kuraoncology.com/>

Note 1: Because the Company discontinued clinical trials of KHK4083/AMG 451 (rocatinlimab) for moderate to severe atopic dermatitis, prurigo nodularis, and moderate to severe asthma, the relevant development information has been removed from this table.

2: Our main progress from March 31, 2026 is as follows.

On April 24, 2026, it was announced that dosing of ziftomenib had commenced for the first patient in the Phase II trial in Japan targeting relapsed or refractory NPM1-

## Major Applications and Approvals

As of Mar. 31, 2026

Code Name, Generic Name, Product Name	Indication	Application/Under Review	Countries/Regions Received Approval in 2026
OTL-200(atidarsagene autotemcel, Product name in Europe/US : Libmeldy/Lenmeldy)	Metachromatic Leukodystrophy (MLD)	filed in Japan	-